Published in Protein Sci on May 01, 2004
Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci U S A (2007) 1.50
Localization of regions in CD46 that interact with adenovirus. J Virol (2005) 1.08
Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics. Biophys J (2006) 0.94
SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer. PLoS One (2012) 0.89
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells. Cell Mol Neurobiol (2015) 0.78
Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1). Malar J (2011) 0.78
Comparative analyses of glycerotoxin expression unveil a novel structural organization of the bloodworm venom system. BMC Evol Biol (2017) 0.75
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. Biochemistry (1989) 10.50
Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. Biophys J (2000) 7.40
Complement. Second of two parts. N Engl J Med (2001) 6.32
Backbone dynamics of Escherichia coli ribonuclease HI: correlations with structure and function in an active enzyme. J Mol Biol (1995) 5.58
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol (1991) 4.27
Backbone dynamics of calmodulin studied by 15N relaxation using inverse detected two-dimensional NMR spectroscopy: the central helix is flexible. Biochemistry (1992) 4.25
Structure and distribution of modules in extracellular proteins. Q Rev Biophys (1996) 3.10
Structure-function relationships of the complement components. Immunol Today (1989) 2.74
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Dynamic activation of protein function: a view emerging from NMR spectroscopy. Nat Struct Biol (2001) 2.57
Protein dynamics from NMR. Nat Struct Biol (2000) 2.52
Measurement of HN-H alpha J couplings in calcium-free calmodulin using new 2D and 3D water-flip-back methods. J Biomol NMR (1994) 2.50
Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem (2000) 1.84
Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell (2001) 1.80
Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. EMBO J (1999) 1.73
Solution structure of a pair of complement modules by nuclear magnetic resonance. J Mol Biol (1993) 1.68
Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev (2001) 1.67
Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology (2000) 1.58
Structure-function relationships of complement receptor type 1. Immunol Rev (2001) 1.47
Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci U S A (1991) 1.34
Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J Immunol (1998) 1.30
CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 1.27
Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell (2002) 1.25
Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem (1994) 1.24
The N-glycan of the SCR 2 region is essential for membrane cofactor protein (CD46) to function as a measles virus receptor. J Virol (1996) 1.12
Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem (1998) 1.09
Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1-2. Virology (1997) 1.08
Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J Biol Chem (2002) 1.05
Independently melting modules and highly structured intermodular junctions within complement receptor type 1. Biochemistry (1999) 1.04
Backbone dynamics of the N-terminal domain in E. coli DnaJ determined by 15N- and 13CO-relaxation measurements. Biochemistry (1999) 1.03
Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein. J Mol Biol (2001) 1.03
Human complement receptor type 1 (CR1) binds to a major malarial adhesin. Trends Mol Med (2002) 0.98
Solution structure of the calponin CH domain and fitting to the 3D-helical reconstruction of F-actin:calponin. Structure (2002) 0.97
Solution structure of a functionally active fragment of decay-accelerating factor. Proc Natl Acad Sci U S A (2003) 0.94
Central modules of the vaccinia virus complement control protein are not in extensive contact. Biochem J (1999) 0.94
Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur J Biochem (1999) 0.91
Binding of soluble 125I-human C3b, the third component of complement, to specific receptors in human cultured B lymphoblastoids cells: characterization of a low affinity interaction. J Immunol (1980) 0.88
Identification of a PU.1-IRF4 protein interaction surface predicted by chemical exchange line broadening. Proc Natl Acad Sci U S A (2003) 0.86
Co-operativity between modules within a C3b-binding site of complement receptor type 1. FEBS Lett (1999) 0.84
Backbone dynamics of the human CC chemokine eotaxin: fast motions, slow motions, and implications for receptor binding. Protein Sci (1999) 0.83
The dynamic behavior of CheW from Thermotoga maritima in solution, as determined by nuclear magnetic resonance: implications for potential protein-protein interaction sites. Biophys Chem (2002) 0.83
Use of site-specific mutagenesis and monoclonal antibodies to map regions of CD46 that interact with measles virus H protein. Virology (1999) 0.83
Three-dimensional structure and flexibility of proteins of the RCA family - a progress report. Biochem Soc Trans (2002) 0.79
Conformational dynamics and molecular recognition: backbone dynamics of the estrogen receptor DNA-binding domain. J Mol Biol (1999) 0.79
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Drop-based microfluidic devices for encapsulation of single cells. Lab Chip (2008) 2.90
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Adenovirus type 11 uses CD46 as a cellular receptor. J Virol (2003) 2.52
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Structural basis for complement factor H linked age-related macular degeneration. J Exp Med (2007) 2.02
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
The pluripotency rheostat Nanog functions as a dimer. Biochem J (2008) 1.97
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci U S A (2010) 1.91
A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 1.89
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci (2009) 1.86
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol (2006) 1.81
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 1.67
Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol (2006) 1.63
Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun (2008) 1.57
Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol (2010) 1.55
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood (2007) 1.53
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med (2011) 1.52
Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol (2002) 1.51
Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J Biol Chem (2006) 1.48
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Cerebrospinal fluid apolipoprotein E concentration decreases after seizure. Seizure (2010) 1.45
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol (2012) 1.40
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (2012) 1.39
An atomic resolution model for assembly, architecture, and function of the Dr adhesins. Mol Cell (2004) 1.37
CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol (2005) 1.37
Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J Biol Chem (2007) 1.36
New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle (2008) 1.35
CD46: expanding beyond complement regulation. Trends Immunol (2004) 1.32
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol (2005) 1.31
Statistical interaction in human genetics: how should we model it if we are looking for biological interaction? Nat Rev Genet (2010) 1.28
Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3. J Biol Chem (2008) 1.28
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 1.28
Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab (2011) 1.27
Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell (2002) 1.25
Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem (2001) 1.22
Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol (2006) 1.21
Large-scale modelling as a route to multiple surface comparisons of the CCP module family. Protein Eng Des Sel (2005) 1.17
Two-dimensional universal conductance fluctuations and the electron-phonon interaction of surface states in Bi2Te2Se microflakes. Sci Rep (2012) 1.17
A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol (2009) 1.16
The role of the immune response in age-related macular degeneration. Int J Inflam (2013) 1.16
Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations. J Biol Chem (2008) 1.16
Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46. J Biol Chem (2003) 1.16
Emerging roles and new functions of CD46. Springer Semin Immunopathol (2005) 1.16
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic (2013) 1.14
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae. J Cell Biol (2002) 1.14
Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther (2008) 1.13
Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation (2009) 1.13
Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2007) 1.12
Mapping QTL for multiple traits using Bayesian statistics. Genet Res (Camb) (2009) 1.10
Functional anatomy of complement factor H. Biochemistry (2013) 1.10
Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood (2005) 1.10
Comparative study of SBP-box gene family in Arabidopsis and rice. Gene (2007) 1.09
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif (2010) 1.09
Localization of regions in CD46 that interact with adenovirus. J Virol (2005) 1.08
Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol (2004) 1.07
Surviving mousepox infection requires the complement system. PLoS Pathog (2008) 1.07
Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol (2013) 1.07
Induction of a regulatory phenotype in human CD4+ T cells by streptococcal M protein. J Immunol (2005) 1.07
Toxicological characteristics of nanoparticulate anatase titanium dioxide in mice. Biomaterials (2009) 1.06
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol (2008) 1.05
Electron transport properties of atomic carbon nanowires between graphene electrodes. J Am Chem Soc (2010) 1.05
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother (2012) 1.05
The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors. J Biol Chem (2005) 1.05
Membrane protein Crry maintains homeostasis of the complement system. J Immunol (2008) 1.04
Molecular evolution of the CPP-like gene family in plants: insights from comparative genomics of Arabidopsis and rice. J Mol Evol (2008) 1.04
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med (2014) 1.03
The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther (2007) 1.03
Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart Study using association and structural equation modeling methods. BMC Proc (2009) 1.03